Authors

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Latest:

Gifts from Walther, Regenstrief Foundations Create Cancer Informatics Chair at IU Simon Comprehensive Cancer Center

Gifts totaling $3 million will create an endowed chair in cancer informatics at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Denis M. Gilmore, MD

Sunandana Chandra, MD, Northwestern Medicine

Latest:

Advances in the Treatment of Malignant Melanoma

Morgane Cheminant, MD, PhD

Morgane Cheminant, MD, PhD, is a member of the Service d’Hematologie adultes at the Hopital Universitaire Necker Enfants Malades, AP-HP

Latest:

Mantle Cell Lymphoma: Evolving Strategies in Diagnosis & Treatment

Kami J. Maddocks, MD; and Morgane Cheminant, MD, PhD, discuss evolving strategies in the diagnosis and treatment of mantle cell lymphoma.

Skyler B. Johnson, MD

Latest:

Fellows Can Join the Fight Against Cancer Misinformation Online

Many cancer organizations across the United States and internationally acknowledge a need for in-novative uses of social technology to improve cancer-related support and information provision.

Jiahn Choi, PhD

Latest:

The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality

One of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.

Nathan Bahary, MD, PhD

Latest:

Dr. Bahary on the Benefits of Ivosidenib in IDH1-Mutated Cholangiocarcinoma

Nathan Bahary, MD, PhD, discusses the benefits of ivosidenib in patients with intrahepatic cholangiocarcinoma whose tumors harbor IDH1 mutations.

Kimberly Cannavale, MPH

Latest:

Cannavale on the Importance of Assessing Comorbidities and Remission Rates in Ovarian Cancer

Kimberly Cannavale, MPH, discusses the clinical implications of a study on the impact of pre-existing comorbidities on remission rates in ovarian cancer.

Andrea Facciabene, PhD

Latest:

Dr. Facciabene on Radiation Bridging Therapy Prior to CAR T-Cell Therapy in Mice Models

Andrea Facciabene, PhD, discusses investigating the use of bridging radiation therapy prior to CAR T-cell therapy in mice models.

Daniel Carrizosa, MD, MS

Latest:

Dr. Carrizosa on the Prevalence of NRG1 Gene Fusions in Solid Tumors

Daniel Carrizosa, MD, MS, discusses the prevalence of NRG1 gene fusions in solid tumors.

Alexis LeVee, MD

Alexis LeVee, MD, is chief Hematology & Medical Oncology fellow at City of Hope

Latest:

Dr LeVee on Limitations of the ASCENT-04 Trial of Sacituzumab Govitecan Plus Pembrolizumab in TNBC

Alexis LeVee, MD, discusses the clinical implications of the ASCENT-04 trial data for patients with TNBC who relapse following prior PD-1 or PD-L1 therapy.

Sarki A. Abdulkadir, MD, PhD

Latest:

Dr. Abdulkadir on the Challenges of Targeting MYC in Prostate Cancer

Sarki A. Abdulkadir, MD, PhD, discusses the challenges of targeting MYC in prostate cancer.

David A. Frank, MD, PhD, FACP

David A. Frank, MD, PhD, FACP, is the director of the Division of Hematology and a professor in Emory University School of Medicine's Department of Hematology and Medical Oncology. He also serves as director of the Winship Innovation Initiative and as an advisor to the Morningside Center for Innovative and Affordable Medicine within the Woodruff Health Sciences Center.

Latest:

Frank’s Path to Advancing Hematology Through Innovation and Discovery: With Girindra Raval, MD; and David A. Frank, MD, PhD, FACP

Girindra Raval, MD, and David A. Frank, MD, PhD, FACP, discuss Frank’s journey, through his undergraduate studies at MIT, and completion of an MD/PhD program at Yale University.

Costanza Lo Cascio, PhD

Latest:

A New Take on Preclinical Drug Trials for GBM Treatment

The Ivy Brain Tumor Center at Barrow Neurological Institute in Phoenix, Arizona, is attempting to subvert this pattern of clinical failure for promising therapeutics by changing the way preclinical studies are developed and conducted to assess the efficacy of drugs for GBM.

Anita Johnson, MD, FACS

Latest:

Dr. Johnson on Racial Disparities in Outcomes Across Multiple Tumor Types

Anita Johnson, MD, FACS, discusses racial disparities in outcomes across multiple tumor types.

Krish Patel, MD, Swedish Cancer Institute

Latest:

Novel Therapies for R/R Follicular Lymphoma

A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.

Efstathios Kastritis, MD

Latest:

Dr Kastritis on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis

Efstathios Kastritis, MD, discusses the background of birtamimab and the rationale for investigating the agent in combination with standard-of-care chemotherapy in newly diagnosed patients with Mayo Stage IV amyloid light chain amyloidosis in the phase 3 AFFIRM-AL trial.

Aimaz Afrough, MD

Latest:

Bispecific Antibodies for the Treatment of RRMM in the Post CAR T Setting

Panelists discuss how the transition from chimeric antigen receptor T-cell therapy (CAR T) to bispecific antibodies depends on disease progression and clinical status, with the choice of bispecific antibody being guided by prior therapy and target antigen, preferring B-cell maturation antigen (BCMA) bispecifics for BCMA-exposed patients and GPRC5D bispecifics for those with BCMA-relapsed disease.

Adam Lee

Latest:

How Health Economics Leverages Clinical Research to Advance Patient Care: With D. Ross Camidge, MD, PhD; and Adam Lee

Camidge and Lee discussed Lee's professional journey and personal insights gained from years of working at the intersection of clinical research and patient care.

Timothy I Shaw, PhD

Latest:

Dr Shaw on the Heterogeneity Between Paired Primary and Metastatic Solid Tumors

Timothy I Shaw, PhD, discusses the genetic heterogeneity between paired primary and metastatic solid tumors, as well as the implications for neoantigen-based personalized vaccines in cancer care.